Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4750370 | 0.82 | CHRM1 (0.45) | LMNA | |
| SCHEMBL28060232 | 0.82 | CHRM1 (0.45) | LMNA | |
| SCHEMBL28737795 | 0.82 | CHRM1 (0.45) | LMNA | |
| SCHEMBL8967631 | 0.78 | SIGMAR1 (0.47) | CYP2B6CYP2D6SLC6A3SIGMAR1LTA4H | |
| SCHEMBL9366900 | 0.75 | CYP2B6 (0.49) | CYP2B6CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL27845833 | 0.75 | SLC6A2 (0.50) | CYP2B6SLC6A2TAAR1CYP1A2CYP2C19 | |
| SCHEMBL6987020 | 0.74 | CYP2B6 (0.43) | CYP2B6SLC6A2TAAR1LMNACYP2D6 | |
| SCHEMBL4684599 | 0.74 | SLC6A9 (0.41) | CYP2B6SLC6A2TAAR1LMNACYP2D6 | |
| SCHEMBL9284783 | 0.74 | SIGMAR1 (0.40) | CYP2B6CYP1A2CYP2C9CYP2C19LMNA | |
| SCHEMBL15820622 | 0.73 | SLC6A2 (0.42) | SLC6A2TAAR1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140904-B1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6800636-B2 | FOR THERAPY OF CANCER | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | GUZI TIMOTHY (US) | 2003-02-27 | — | — | US | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | FNTA, FNTB, CETP | CYP2B6 3158/4885SLC6A2 4508/4885TAAR1 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.